Suppr超能文献

分析胰腺癌及癌旁组织中 METTL14 的表达及其对患者预后的预测价值。

Analysis of METTL14 expression in pancreatic cancer and adjacent tissues and its prognostic value for patient outcomes.

机构信息

Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, 110000, China.

Department of General Surgery, Shengjing Hospital Affiliated to China Medical University Shenbei Campus, No. 16 Puhe Avenue, Shenbei New District, Shenyang, 110000, Liaoning Province, China.

出版信息

Clin Exp Med. 2024 Nov 11;25(1):3. doi: 10.1007/s10238-024-01506-w.

Abstract

This study aims to analyze the differential expression of METTL14 in pancreatic cancer (PC) tissues and adjacent normal tissues, and its correlation with clinical outcomes. According to the inclusion and exclusion criteria, a total of 80 patients diagnosed in our hospital from January 2021 to January 2023 were chosen as research subjects. RTQ-PCR has detected the mRNA level expression of METTL14 in cancer and para-cancerous tissues. Immunohistochemistry was used to detect the protein expression of METTL14 in cancer and para-cancerous tissues. To compare the relationship between METTL14 expression and clinicopathological parameters in different PC patients. Kaplan-Meier survival analysis of the relationship between METTL14 expression in PC tissues and patient survival prognosis. The Multifactor COX model evaluates factors affecting the prognosis of PC. The expression level of METTL14 mRNA in PC tissues was 5.51 ± 0.35 (kDa), and the positive rate of METTL14 protein expression in PC tissues of all patients was 73.75 (59/80). Tumor location (P = 0.012), tumor differentiation degree (P = 0.028), tumor AJCC stage (P = 0.000), and lymph node metastasis (P = 0.000) were significantly related to the positive rate of METTL14 protein expression in PC tissue. Follow-up results showed that among 80 patients, 63 died. The three-year survival rate of the METTL14 positive group was 13.56% (8/59), and the three-year survival rate of the negative group was 42.86% (9/21). The difference in the three-year survival rate between METTL14 positive and negative expression groups was statistically significant (P = 0.031). Multivariate COX regression analysis results showed that METTL14 was positive (OR 2.797, 95% CI 1.233-5.877), tumor AJCC stage II-III (OR 1.628, 95% CI 1.435-3.859) and lymph node metastasis (OR 1.733, 95% CI 1.122-2.372) were substantive risk factors for poor prognosis in patients with PC. METTL14 expression increases in PC tissue, which is related to tumor AJCC stage, tumor differentiation, and lymph node metastasis, and can be evaluated in the survival prognosis of patients with PC.

摘要

本研究旨在分析 METTL14 在胰腺癌(PC)组织和相邻正常组织中的差异表达及其与临床结局的相关性。根据纳入和排除标准,选择了 2021 年 1 月至 2023 年 1 月在我院诊断的 80 例患者作为研究对象。RTQ-PCR 检测了癌症和癌旁组织中 METTL14 的 mRNA 水平表达。免疫组织化学法检测了癌症和癌旁组织中 METTL14 的蛋白表达。比较不同 PC 患者 METTL14 表达与临床病理参数的关系。Kaplan-Meier 生存分析 PC 组织中 METTL14 表达与患者生存预后的关系。多因素 COX 模型评估影响 PC 患者预后的因素。PC 组织中 METTL14mRNA 的表达水平为 5.51±0.35(kDa),80 例患者 PC 组织中 METTL14 蛋白表达的阳性率为 73.75%(59/80)。肿瘤位置(P=0.012)、肿瘤分化程度(P=0.028)、肿瘤 AJCC 分期(P=0.000)和淋巴结转移(P=0.000)与 PC 组织中 METTL14 蛋白表达的阳性率显著相关。随访结果显示,80 例患者中 63 例死亡。METTL14 阳性组的 3 年生存率为 13.56%(8/59),阴性组为 42.86%(9/21)。METTL14 阳性和阴性表达组的 3 年生存率差异有统计学意义(P=0.031)。多因素 COX 回归分析结果显示,METTL14 阳性(OR=2.797,95%CI=1.233-5.877)、肿瘤 AJCC 分期 II-III(OR=1.628,95%CI=1.435-3.859)和淋巴结转移(OR=1.733,95%CI=1.122-2.372)是 PC 患者预后不良的实质性危险因素。METTL14 在 PC 组织中的表达增加与肿瘤 AJCC 分期、肿瘤分化和淋巴结转移有关,可用于评估 PC 患者的生存预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4618/11554755/9aabd78b957a/10238_2024_1506_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验